These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 6703716)

  • 21. [Pharmacy standards for clinical trials].
    Terkola R
    Onkologie; 2008; 31 Suppl 2():25-8. PubMed ID: 18487865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quality assurance of clinical studies with production drugs.
    McCormack JF
    Qual Assur; 1997; 5(1):55-9. PubMed ID: 9170175
    [No Abstract]   [Full Text] [Related]  

  • 23. Objective response criteria in phase II and phase III studies.
    Jones WG; Akaza H; Van Oosterom AT; Kotake T
    Prog Clin Biol Res; 1988; 269():243-60. PubMed ID: 3293063
    [No Abstract]   [Full Text] [Related]  

  • 24. [The revision of Guidelines for Clinical Evaluation Methods of Anti-Cancer Drugs in Japan].
    Andoh M; Fujiwara Y; Shimada Y
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):1015-9. PubMed ID: 16878363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selecting promising ALS therapies in clinical trials.
    Glass JD; Benatar M; Polak M
    Neurology; 2007 May; 68(18):1545-6; author reply 1546. PubMed ID: 17470765
    [No Abstract]   [Full Text] [Related]  

  • 26. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
    Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
    Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Essential conditions for the development of new anticancer drugs based on ICH-GCP].
    Saijo N
    Gan To Kagaku Ryoho; 1998 Apr; 25(5):671-84. PubMed ID: 9571964
    [No Abstract]   [Full Text] [Related]  

  • 28. Good clinical practice--a practical experience.
    Ogunsola FT
    Nig Q J Hosp Med; 2008; 18(2):123-4. PubMed ID: 19068567
    [No Abstract]   [Full Text] [Related]  

  • 29. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise].
    Ekimoto H
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. End points in cancer clinical trials and the drug approval process.
    Schilsky RL
    Clin Cancer Res; 2002 Apr; 8(4):935-8. PubMed ID: 11948095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Is the placebo still ethically acceptable and scientifically useful in clinical drug experimentation?].
    Mariani L; Ventresca GP
    Clin Ter; 1996 Nov; 147(11):595-8. PubMed ID: 9264914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Criteria supporting the study of drugs in the newborn.
    Ward RM; Benitz WE; Benjamin DK; Blackmon L; Giacoia GP; Hudak M; Lasky T; Rodriguez W; Selen A
    Clin Ther; 2006 Sep; 28(9):1385-98. PubMed ID: 17062311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experimental evaluation of antitumor drugs in the USA and USSR and clinical correlations.
    Natl Cancer Inst Monogr; 1980 Dec; (55):1-179. PubMed ID: 7010179
    [No Abstract]   [Full Text] [Related]  

  • 35. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Takimoto CH
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiarrhythmic drug approval--the Health Protection Branch perspective.
    Znamirowska M
    Can J Cardiol; 1991; 7(1):47-8; discussion 49-50. PubMed ID: 2025793
    [No Abstract]   [Full Text] [Related]  

  • 37. [Development of an anticancer drug in Japan based on a new clinical trial system].
    Nakashima H; Nakano S
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):287-94. PubMed ID: 9492818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecularly targeted oncology therapeutics and prolongation of the QT interval.
    Strevel EL; Ing DJ; Siu LL
    J Clin Oncol; 2007 Aug; 25(22):3362-71. PubMed ID: 17664484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigational new drug, antibiotic, and biological product applications; clinical hold and termination--FDA. Final rule.
    Fed Regist; 1992 Apr; 57(73):13244-9. PubMed ID: 10118458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Drug testing today].
    Domschke S; Domschke W
    Fortschr Med; 1981 Jun; 99(21):814-8. PubMed ID: 7250872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.